Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK | MicrobiomeTrials← Back to trialsNCT06358573
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-10-24Est. Completion: 2028-10
Enrollment target: 61 participants Locations- Centre de lutte contre le cancer Léon Bérard, Lyon, France
- Tumor Zentrum Aarau, Aarau, Switzerland
- St. Claraspital, Basel, Switzerland
- EOC - IOSI Ospedale regionale Bellinzona e valli - San Giovanni, Bellinzona, Switzerland
- Kantonsspital Graubünden, Chur, Switzerland
- Kantonsspital Baselland, Liestal, Switzerland
- HOCH Health Ostschweiz, Sankt Gallen, Switzerland
- TBZO - Tumor- & Brustzentrum Ostschweiz, Sankt Gallen, Switzerland
- Kantonsspital Winterthur, Winterthur, Switzerland
- Universitätsspital Zürich - Klinik für Gynäkologie, Zurich, Switzerland
Other microbiome trials you might be interested in
Metastatic Breast CancerMetastatic Solid Cancer
This phase II study aims to confirm the diagnostic performance and accuracy of 68Ga-ABS011 PET/CT in determining the HER…
Innsbruck, AustriaEst. completion Dec 31, 2026
Solid Tumours
This study is open to adults with advanced or metastatic solid cancer, such as non-small cell lung cancer, head and neck…
Leuven, BelgiumEst. completion Jan 15, 2030
Phase 1
Recruiting
Triple-Negative Breast Cancer (TNBC)Gastric Cancer (GC)Gastric Cancer Adenocarcinoma MetastaticOvarian Cancer MetastaticOvarian Cancer Metastatic RecurrentHead and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)Hepatocellular Carcinoma MetastaticClassical Hodgkin Lymphoma RelapsedCutaneous T-Cell Lymphoma/Mycosis FungoidesCutaneous T-Cell Lymphoma/Sezary SyndromeCutaneous T-Cell LymphomasPeripheral T-cell Lymphoma (PTCL)Large Granular Lymphocytic Leukemia (LGL-L)T-Cell Large Granular Lymphocytic Leukemia
This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced sol…
Multiple LocationsEst. completion Aug 2029